Advanced Oncotherapy (AVO) announces that the Radio Frequency Power tests of the first Coupled Cavity Linac unit have been successfully completed at the Company’s testing facility at CERN in line with expectations.
The RF Power units, created by ScandiNova Systems AB, generate the high-power needed to accelerate protons to speeds whereby they can effectively target cancer cells. The RF Power units include the modulator, for the early delivery of which, our partner ScandiNova accepted part payment in shares as announced on 2 April 2015.
This announcement follows the successful completion in January of the LIGHT system’s first CCL unit, an accelerating structure that consists of a series of cells that accelerate protons from energies of 37.5 Mega-electron Volts (MeV) to the full 230MeV required to treat all radiosensitive tumours.
On 1 May 2015 the Company announced a successful £20m fundraise net of expenses to continue the development of its LIGHT system, with the first unit expected to be installed in Harley Street, London, by the end of 2016 and first patient treatments expected in 2017.
Commenting, Sanjeev Pandya, CEO of Advanced Oncotherapy, said: “In November last year we gave investors a clear pathway towards the delivery of our first LIGHT system and I am delighted that we continue to deliver to this timetable on time and to budget, with the successful RF Power testing of the first CCL unit. Our recent funding has provided the Company with the financial security that we need to deliver our ground-breaking proton therapy technology which we expect will be treating patients in the heart of London in 2017.”
Advanced Oncotherapy Plc
Sanjeev Pandya, CEO
Tel: +44 20 3617 8728
Nicolas Serandour, CFO
Westhouse Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten
Tel: +44 20 7601 6100
Beaufort Securities (Joint Broker)
Saif Janjua / Jon Levinson
Tel: +44 20 7382 8300
Walbrook PR (Financial PR & IR)
Tel: +44 20 7933 8780 or firstname.lastname@example.org
Paul McManus / Anna Dunphy
Mob: +44 7980 541 893 / Mob: +44 7876 741 001